GUANIDINE CARBONATE

US Previously Marketed

First approved in 1939

Details

Stereochemistry	ACHIRAL
Molecular Formula	2CH5N3.CH2O3
Molecular Weight	180.1658
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(N)=N.NC(N)=N.OC(O)=O

InChI

InChIKey=STIAPHVBRDNOAJ-UHFFFAOYSA-N

InChI=1S/2CH5N3.CH2O3/c3*2-1(3)4/h2*(H5,2,3,4);(H2,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel 16 Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21926190	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Eaton-Lambert syndrome 5 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	Palliative		Approved 8429	GUANIDINE HYDROCHLORIDE Approved Use Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date 1939

PubMed

Title	Date	PubMed
Characterization of the denatured states distribution of neocarzinostatin by small-angle neutron scattering and differential scanning calorimetry.	2001 Apr 3	11300776
Intensely positively charged perineuronal nets in the adult rat brain as detected by staining with anionic iron colloid.	2001 Feb	11310504
Metric engineering of soft molecular host frameworks.	2001 Feb	11263869
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].	2001 Feb	11218725
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.	2001 Feb	11168991
Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells.	2001 Feb 16	11178976
Molecular specificities of antibodies against ovine and murine recombinant prion proteins.	2001 Feb 16	11178966
The folding nucleus of a fibronectin type III domain is composed of core residues of the immunoglobulin-like fold.	2001 Feb 2	11162123
Solid-phase guanidinylation as a diversification strategy of poly-L-proline type II peptide mimic scaffolds.	2001 Feb 22	11178825
Disulfide-dependent folding and export of Escherichia coli DsbC.	2001 Jan 12	11042167
Distributions of intramolecular distances in the reduced and denatured states of bovine pancreatic ribonuclease A. Folding initiation structures in the C-terminal portions of the reduced protein.	2001 Jan 9	11141061
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores.	2001 Jan-Feb	11148071
Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator.	2001 Jun 8	11304524
Proteoglycans and hyaluronan in human fetal membranes.	2001 Mar	11262472
Characterization of carbonic anhydrase from Neisseria gonorrhoeae.	2001 Mar	11248679
Major differences in stability and dimerization properties of two chimeric mutants of human stefins.	2001 Mar 1	11170205
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.	2001 Mar 30	11266439
The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling: fractionation of conformational isomers of alpha-lactalbumin.	2001 Mar 30	11118458
Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus.	2001 May 11	11278952
Replacement of thrombin residue G184 with Lys or Arg fails to mimic Na+ binding.	2001 May 15	11288181

Patents

Sample Use Guides

In Vivo Use Guide

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.

Route of Administration: Oral

In Vitro Use Guide

Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.

Name

Type

Language

GUANIDINE CARBONATE

Official Name

English

NSC-2171

Code

English

GUANIDINE CARBONATE [INCI]

Common Name

English

CARBONIC ACID, COMPD. WITH GUANIDINE (1:2)

Common Name

English

DIGUANIDINIUM CARBONATE

Systematic Name

English

GUANIDINE CARBONATE (2:1)

Systematic Name

English

BISGUANIDINIUM CARBONATE

Systematic Name

English

GUANIDINIUM CARBONATE

Systematic Name

English

Code System Code Type Description

ECHA (EC/EINECS)

209-813-7